Stayble Therapeutics AB (STABL) — Cash Flow Reinvestment Rate

Latest as of December 2019: 0.00x

Stayble Therapeutics AB (STABL) has a Cash Flow Reinvestment Rate of 0.00x as of December 2019, reinvesting Skr0.00 (capex Skr0.00 ) from operating cash flow of Skr3.76 Million. See free cash flow generation of Stayble Therapeutics AB to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.00x
(Capex + Investments) / Operating CF

Total Reinvested

Skr0.00
Capex + Investments

Operating Cash Flow

Skr3.76 Million
SEK

Capital Expenditures

Skr0.00
SEK

Stayble Therapeutics AB Cash Flow Reinvestment Rate (2019–2019)

Historical reinvestment intensity for Stayble Therapeutics AB across 1 annual periods. For the full cash flow conversion analysis, see STABL operating cash flow.

Annual Cash Flow Reinvestment Rate for Stayble Therapeutics AB (2019–2019)

Year-by-year capital reinvestment analysis for Stayble Therapeutics AB. See Stayble Therapeutics AB financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (SEK) Operating CF Capex YoY Change
2019 0.00x Skr1.00K Skr289.39K Skr0.00 —
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow